191 related articles for article (PubMed ID: 24322475)
1. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.
Abrahamsen B; Grove EL; Vestergaard P
Osteoporos Int; 2014 Feb; 25(2):757-62. PubMed ID: 24322475
[TBL] [Abstract][Full Text] [Related]
2. Cardiac concerns associated with strontium ranelate.
Reginster JY
Expert Opin Drug Saf; 2014 Sep; 13(9):1209-13. PubMed ID: 25020233
[TBL] [Abstract][Full Text] [Related]
3. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
Cooper C; Fox KM; Borer JS
Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
[TBL] [Abstract][Full Text] [Related]
4. The position of strontium ranelate in today's management of osteoporosis.
Reginster JY; Brandi ML; Cannata-Andía J; Cooper C; Cortet B; Feron JM; Genant H; Palacios S; Ringe JD; Rizzoli R
Osteoporos Int; 2015 Jun; 26(6):1667-71. PubMed ID: 25868510
[TBL] [Abstract][Full Text] [Related]
5. Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Svanström H; Pasternak B; Hviid A
Ann Rheum Dis; 2014 Jun; 73(6):1037-43. PubMed ID: 24651624
[TBL] [Abstract][Full Text] [Related]
6. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
9. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
Osborne V; Layton D; Perrio M; Wilton L; Shakir SA
Drug Saf; 2010 Jul; 33(7):579-91. PubMed ID: 20553059
[TBL] [Abstract][Full Text] [Related]
10. Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.
Atteritano M; Catalano A; Santoro D; Lasco A; Benvenga S
Endocrine; 2016 Jul; 53(1):305-12. PubMed ID: 26304851
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice.
Donneau AF; Reginster JY
Osteoporos Int; 2014 Feb; 25(2):397-8. PubMed ID: 24322477
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
Hiligsmann M; Ben Sedrine W; Bruyère O; Reginster JY
Osteoporos Int; 2013 Aug; 24(8):2291-300. PubMed ID: 23371359
[TBL] [Abstract][Full Text] [Related]
13. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey E; Kanis JA
Osteoporos Int; 2010 Feb; 21(2):339-49. PubMed ID: 19513577
[TBL] [Abstract][Full Text] [Related]
15. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years.
Audran M; Jakob FJ; Palacios S; Brandi ML; Bröll H; Hamdy NA; McCloskey EV
Rheumatol Int; 2013 Sep; 33(9):2231-9. PubMed ID: 23455629
[TBL] [Abstract][Full Text] [Related]
16. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance.
Berencsi K; Sami A; Ali MS; Marinier K; Deltour N; Perez-Gutthann S; Pedersen L; Rijnbeek P; Van der Lei J; Lapi F; Simonetti M; Reyes C; Sturkenboom MCJM; Prieto-Alhambra D
Osteoporos Int; 2020 Apr; 31(4):721-755. PubMed ID: 31696274
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
19. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
20. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
Rolland Y; Abellan Van Kan G; Gillette-Guyonnet S; Roux C; Boonen S; Vellas B
Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
